Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MITHRIDATE first-line treatment trial in high-risk polycythemia vera
2024-516109-21-00Phase 3Authorised
- Sponsor
- University of Birmingham
- Start
- Dec 2024
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in polycythemia vera (PV) comparing Ruxolitinib, Hydroxycarbamide and Peginterferon alfa-2a (3 arms). Primary endpoint: Event-free survival. Planned start Dec 2024; status: authorised.
02
Drugs
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on 2024-516109-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516109-21-00.